WO2014054841A1

WO2014054841A1 - Composition comprising material for controlling expression of abh antigen

Info

Publication number: WO2014054841A1
Application number: PCT/KR2013/001756
Authority: WO
Inventors: 홍용덕; 신송석; 한상훈; 김겸손; 정진호; 오장희
Original assignee: (주)아모레퍼시픽
Priority date: 2012-10-05
Filing date: 2013-03-05
Publication date: 2014-04-10
Also published as: KR20140044454A; KR101449129B1

Abstract

The present invention relates to an anti-aging or skin moisturizing composition. The composition according to the present invention contains, as an active ingredient, a material for controlling the expression of ABH antigen, and therefore, has superior anti-aging and skin moisturizing effects. Further, the composition of the preset invention may inhibit the expression of MMP-1, and therefore, can be effectively used in reducing wrinkles or improving the appearance thereof.

Description

【Specification】

[Name of invention]

A composition comprising a substance that modulates the expression of an ABH antigen

Technical Field

The present invention relates to an anti-aging or moisturizing composition.

Background Art

Blood type antigens refer to specific antigenic striking structures found in glycoproteins or glycolipids on the surface of blood red blood cells. Representative examples include AB0 blood type antigens (ABH antigens) and Lewis type blood type antigens. Blood types are determined according to the glycosylation terminal group structure of a specific structure. AB0 blood type antigens and Lewis blood type antigens are not only expressed in red blood cells, but are found in various parts of the human body. In particular, AB0 blood type antigens are expressed in the epithelium of the esophagus, stomach, and small intestine, depending on the individual's blood type. It is known and is expressed in the granular layer of the epidermis in the skin.

The expression of the granular layer of the epidermis of the AB0 blood group antigen is shown in the outermost layer of the skin anatomically and is closely related to skin-related diseases, particularly inflammatory diseases.

AB0 blood group antigens are very important antigens for the rejection of blood transfusions and organ transplants, but since their discovery in 1900, little has been studied on physiological functions other than rejection.

The inventors of the present invention have confirmed that the substance regulating the expression of the ABH antigen not only has an anti-aging effect, but also has a skin moisturizing effect, thereby completing the present invention.

[Detailed Description of the Invention]

[Technical problem]

An object of the present invention is to provide a composition that brings anti-aging or moisturizing efficacy.

Technical Solution

In order to achieve the above object, the present invention provides a composition for anti-aging comprising a substance for regulating the expression of the ABH antigen as an active ingredient.

<8> The present invention also provides a moisturizing composition comprising a substance for regulating the expression of the ABH antigen as an active ingredient.

Advantageous Effects

<9> The composition according to the present invention contains a substance for regulating the expression of the ABH antigen as an active ingredient, has an excellent anti-aging and moisturizing effect. The composition of the present invention is also MMP-1 It can be usefully used to alleviate or improve wrinkles by inhibiting expression.

[Brief Description of Drawings]

Figure 1 shows the structure of the ABH antigen and Lewis blood type antigen.

<ιι> Figure 2 is a result of confirming that the expression of B antigens in HaCaT cell line is increased by a substance that controls the expression of ABH antigens.

3 shows the effect of inhibiting the expression of MMP-1 (collagenase) in human skin fibroblasts.

Figure 4 shows the effect of inhibiting the expression of MMP-1 (collagenase) in HaCaT cells.

[Best form for implementation of the invention]

In one aspect, the present invention relates to an anti-aging composition comprising, as an active ingredient, a substance that controls the expression of an ABH antigen.

In the present specification, "ABH antigen" 'glycoprotein black on the surface of red blood cells of the blood refers to a specific antigenic structure expressed in glycolipids, typically ABH antigen is represented ABB antigen represented in Figure 1, Lewis It is used to include all aggregates of ABH antigen analogues, such as blood-type antigens, etc. ABH antigen analogues are substances to which monosaccharides, amino acids, etc. are additionally bound, and mean substances having the same functions as the original functions of ABH antigens. Figure 1 shows the structure of the ABH antigen and Lewis type blood type antigen.

In the present specification, "anti-aging" 'means to slow the change of the body that changes over time, and specifically, examples of improving wrinkles, reducing wrinkles or reducing color deposition such as blotch In the present specification, aging may be delayed by inhibiting the expression of MMP.

As used herein, the term "active ingredient" means a component that can exhibit activity alone or in combination with a carrier having no desired activity.

In the anti-aging composition according to the aspect of the present invention, the agent for controlling the expression of the ABH antigen includes a substance for increasing the expression of the ABH antigen. Increasing the expression of such ABH antigen may be specifically expressed through increased expression of B antigen in HaCaT cell line.

In the anti-aging composition of the present invention, the agent for controlling the expression of the ABH antigen is 1,3-dicaffeoylquinic acid (1,3-dicaffeoylquinic acid), 1,5-dicapeo At least one compound selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable Salts thereof.

[Formula 1]

1,3-dicafTeoylquinic acid

[Formula 2]

, 5-dicaffeoylquinic acid

[Formula 3]

amentoflavon

<25>

As used herein, the term "derivative" means any compound that is changed into another substituent at a substitutable position of the compound, and there is no limitation in the kind of such substituents.

<27> As used herein, "pharmaceutically acceptable" means a conventional medical dosage (medicinal can be approved or approved by the government or equivalent regulatory body for use in animals, more specifically in humans, by avoiding significant toxic effects when used in dosage form, or as listed in a pharmacopeia or other general pharmacopeia. It means to be.

<28> As used herein, "pharmaceutically acceptable salts" are pharmaceutically acceptable and parental.

A salt according to one aspect of the invention having the desired pharmacological activity of a parent compound. The salt is formed by (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfuric acid nitrate, or the like; Or acetic acid, propionic acid, nucleoanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4- Hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane- disulfonic acid, 2-hydroxyethanesulfonic acid, benzenebenzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2 Naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2,2,2] -0-2-ene-1—carboxylic acid, glucoheptonic acid, 3-phenylpropyionic acid Acid addition salts formed with organic acids such as trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid; Or (2) salts formed when the acidic protons present in the parent compound are substituted.

In the anti-aging composition of one aspect of the present invention, the composition may include a substance for controlling the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition.

When the substance that controls the expression of the ABH antigen is used in the above range, it is not only suitable for showing the anti-aging effect of the anti-aging and anti-wrinkle, as intended by the present invention, and also satisfies both the stability and safety of the composition. This is useful in terms of cost effectiveness. In view of the above, the composition of the present invention is 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, 0.02% by weight relative to the total weight of the substance composition for controlling the expression of the ABH antigen % To 18% by weight, 0.025% to 17.5% by weight, 0.03% to 17% by weight, 0.035% to 16.5% by weight, 0.04% to 16% by weight, or 0.045% to 15.5% by weight. have.

<3i> In the antiaging composition according to one aspect of the present invention, the composition is MMP1

can inhibit the expression of matrix metal loproteinases. Specifically, the composition of the present invention may inhibit or inhibit the expression of the MMP1 gene, or may inhibit the activity of the MMP1 protein by inhibiting its activity. The present invention relates to a moisturizing composition comprising, as another active ingredient, a substance that controls the expression of the ABH antigen.

The composition of the present invention can increase the skin moisturizing power by increasing the expression of the ABH antigen.

In a composition of one aspect of the present invention, the material for controlling the expression of the ABH antigen may be a substance that increases the expression of the ABH antigen.

In a composition of one aspect of the present invention, the material for controlling the expression of the ABH antigen is 1,3-dicaffeoylquinic acid (1,3-dicaffeoylquinic acid), 1,5-dicafeoylqui And one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof.

In a composition according to one aspect of the invention, the composition modulates the expression of an ABH antigen.

The material to be degraded may comprise from 0.001 weight ¾ to 20 weight percent relative to the total weight of the composition.

In the case of using a substance that regulates the expression of the ABH antigen in the above range, the present invention is not only suitable for exhibiting the intended moisturizing effect, but also satisfies both the stability and safety of the composition, and the aspect of cost-effectiveness. Useful at In view of the above, the composition of the present invention is a substance that controls the expression of the ABH antigen _, 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, 0.02 to the total weight of the composition Weight% to 18 weight%, 0.025 weight% to 17.5 weight%, 0.03 weight% to 17 weight ¾, 0.035 weight% to 16.5 weight%, 0.04 weight% to 16 weight% or 0.045 weight% to 15.5 weight ¾ Can be.

In a composition which is one aspect of the present invention, the composition may be a cosmetic composition.

The cosmetic composition is not particularly limited in formulation, and may be appropriately selected according to the purpose. For example, supple cream (skin lotion and milk lotion), nourishing cream, essence, nourishing cream, massage cream pack, gel, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder It may be prepared in any one or more formulations selected from the group consisting of body lotion, body cream, body oil and body essence, but is not limited thereto. In addition, the cosmetic composition may include using the formulation of the external preparation for skin in the form of an ointment, a patch.

Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application. Can be. For example, it can be provided in the form of a formulation of emulsion, suspension, solid, gel, powder, paste, foam or aerosol composition obtained by dispersing the oil phase in a solution, aqueous phase. have. Compositions of such formulations may be prepared according to conventional methods in the art.

The cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range of not impairing the main effect, preferably synergistic effects on the main effect. In addition, the cosmetic composition according to the present invention is a moisturizing agent, emollient, purple. The sun absorber, preservatives, fungicides, antioxidants, pH adjusting agents, organic and inorganic pigments, fragrances, coolants or limiting agents may be further included. The blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition Can be.

In a composition of one aspect of the present invention, the composition may be a pharmaceutical composition.

The formulation of the pharmaceutical composition according to the present invention may be a solution, a suspension, an emulsion, a gel, a drop, a suppository, a patch or a spray, but is not limited thereto. The formulations can be easily prepared according to conventional methods in the art, and include excipients, wetting agents, emulsifying accelerators, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizing agents, preservatives, preservatives. Or other commercially available adjuvants may be used as appropriate.

The active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Determination of dosage based on these factors is within the level of one skilled in the art, and its daily dosage is, for example, 0.000025 mg / g / day to 0.025 mg / g / day, more specifically 0.00025 mg / g / day to 0.01 m _g / g / day, but is not limited thereto.

The pharmaceutical composition of the present invention may be administered orally or transdermally, but is not limited thereto.

<46>

In another aspect, the present invention relates to an anti-aging method of administering to a subject an effective amount of a substance that regulates the expression of AβΗ antigen. Applying the method to a subject can inhibit or delay aging of the subject's skin.

In the anti-aging method of one aspect of the present invention, the agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen. Specifically As a substance for regulating the expression of the ABH antigen, 1,3-dicafeoylquinic acid (1,3-dicafeoylquinic acid), 1,5-dicafeoylquinic acid and amentoflavone It may include, but is not limited to, one or more compounds selected from the group consisting of (amentoflavon), derivatives thereof or pharmaceutically acceptable salts thereof.

In the anti-aging method of one aspect of the present invention, the agent for controlling the expression of the ABH antigen may be administered to the subject in the form of a composition, wherein the composition is a substance for controlling the expression of the ABH antigen It may comprise from 0.001% by weight to 20% by weight relative to the total weight of the composition. When using a substance that modulates the expression of the ABH antigen in the above range, not only is it suitable for showing the anti-aging effect of the present invention, but also satisfies both the stability and safety of the composition, and cost-effectiveness aspects Useful at In view of the above, the composition administered in the anti-aging method of one aspect of the present invention is a substance that controls the expression of the ABH antigen is 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight relative to the total weight of the composition, 0.015 wt% to 18.5 wt%, 0.02 wt% ¾ to 18 wt%, 0.025 wt% to 17.5 wt%, 0.03 wt% to 17 wt%, 0.035 wt% to 16.5 wt%, 0.04 wt% to 16 wt%, or 0.045 It may be included in the weight% to 15.5% by weight.

In the anti-aging method of one aspect of the present invention, the substance regulating the expression of the ABH antigen can inhibit the expression of matrix metal loproteinase (MMP1).

In another aspect, the present invention relates to a method of moisturizing skin, comprising administering to a subject an effective amount of a substance that modulates the expression of an ABH antigen.

In the method of moisturizing the skin, which is an aspect of the present invention, the agent for controlling the expression of the ABH antigen may be a substance for increasing the expression of the ABH antigen, and specifically, 1,3-dicafeoylquinic acid ( 1,3-dicaffeoylquinic acid), 1,5-dicafeoylquinic acid (1,5 ᅳ dicafeoylquinic acid) and one or more compounds selected from the group consisting of amentoflavon, derivatives thereof or pharmaceutically acceptable Its salts may be included.

In the method of moisturizing the skin, which is an aspect of the present invention, a substance that controls the expression of the ABH antigen may be administered to a subject in the form of a composition, and the composition may include a substance that modulates the expression of the ABH antigen. It may comprise from 0.001% to 20% by weight relative to the total weight. When a substance that modulates the expression of the ABH antigen is used in the above range, it is not only suitable to exhibit the moisturizing effect intended by the present invention, but also the composition of the composition. Both qualitative and safety can be satisfied and it is useful in terms of cost effectiveness. In view of the above, the composition of the present invention comprises 0.005% by weight to 19.5% by weight, 0.01% by weight to 19% by weight, 0.015% by weight to 18.5% by weight, based on the total weight of the composition 0.02 wt% to 18 wt%, 0.025 wt% to 17.5 wt%, 0.03 wt% to 17 wt%, 0.035 wt% to 16.5 wt%, 0.04 wt% to 16 wt% or 0.045 wt% to 15.5 wt% Can be.

<54>

In another aspect, the present invention may be a substance that controls the expression of an ABH antigen for use in anti-aging. The agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3- dicaffeoylquinic acid (1,3- dicaffeoylquinic acid), 1,5—decaffeinated One or more compounds selected from the group consisting of oilquinic acid (1,5-dicafeoylquinic acid) and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof, but are not limited thereto. Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).

In another aspect, the present invention may be a substance that modulates the expression of an ABH antigen for use in moisturizing the skin. The agent for controlling the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3- dicaf feoylquinic acid (1,3-dicaf feoylquinic acid), 1,5 一It may be, but is not limited to, one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof. . Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).

<57>

In another aspect, the present invention may relate to the anti-aging use of a substance that modulates the expression of an ABH antigen. The agent for regulating the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, specifically 1,3-dicafeoylquinic acid (1,3-dicaf feoylquinic acid), 1,5 one It may be, but is not limited to, one or more compounds selected from the group consisting of 1,5-dicafeoylquinic acid and amentoflavon, derivatives thereof or pharmaceutically acceptable salts thereof. A substance that regulates the expression of the ABH antigen can inhibit the expression of matrix PI (matrix metalloproteinase). In another aspect, the present invention may relate to a skin moisturizing use of a substance that modulates the expression of an ABH antigen. The agent for regulating the expression of the ABH antigen may include a substance for increasing the expression of the ABH antigen, and specifically 1,3-dicafeoylquinic acid (1,3—dicaffeoylquinic acid), 1,5 dicafe One or more compounds selected from the group consisting of oilquinic acid (1,5-dicafeoylquinic acid) and amentoflavon. Water, its derivatives or pharmaceutically acceptable salts thereof, but is not limited thereto. Substances that control the expression of the ABH antigen may inhibit the expression of matrix metalloproteinase (MMP1).

<60>

[Form for implementation of invention]

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only to illustrate the invention, it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.

Example 1

Increased Expression of B Antigen in HaCaT Cell Lines

The effects of various kinds of compounds on the expression of ABH antigens were examined. To this end, HaCaT cells (provided by Prof. Dr. N.E. Fusenig, DKFZ Heidelberg, Germany) were incubated with 10% FBS-DMEM in 35 mm dish and starvated with 0% FBS-DMEM for 24 hours. 1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid and amentoflavones, followed by medium replacement with 0% FBS-DMEM (Amentoflavon) was treated in HaCaT cells at a concentration of 2ug / ml each, and then incubated for 48 hours (control treated with DMS0). Proteins were extracted from the cells, and the cells were lysed in the same amount, and the expression of type B antigen was examined by Western blot. Alpha-leuulin protein was used as a control.

As a result (FIG. 2), 1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid and amentoflavones Both amentoflavon) were found to have an effect of increasing the expression of type B antigen in HaCaT cells.

Example 2

<65> Inhibitory effect of MMP-1 (collagenase) in human skin fibroblasts

<66> the ^fibers' fibroblasts (KF-4109, available from Cloud pictorial) of the person in 60mm dish 1W

After incubation with Dulbecco's Modified Eagle's Media (FBS-DMEM), 0% FBS- Starvation with DMEM. After washing twice with PBS, ultraviolet rays were irradiated. 1,3-dicaf feoylquinic acid, 1,5-dicafeoylquinic acid and amento were changed again with medium of 0% FBS-DMEM. Each flavone (amentoflavon) was treated at a concentration of 2 ug / ml and then incubated for 48 hours (control treated with DMS0). The medium was collected and loaded with the same amount of medium to confirm MMP-1 by Western blot. The protein was extracted from the cells and the same amount of cell lysate was loaded to confirm the expression of alpha-tubulin by Western blot.

As a result (FIG. 3), 1,3—dicafeoylquinic acid, 1,5-dicafeoylquinic acid, and amentopolbonone It was confirmed that both (amentoflavon) had an effect of inhibiting the expression of MMP-1 (collagenase), and in particular, it was confirmed that the effect of amentoflavon was excellent.

Example 3

Inhibition Effect of MIiP-1 (Collagenase) in HaCaT Cells

HaCaT cells (provided by Prof. Dr. N. E. Fusenig, DKFZ Heidelberg,

Germany) was incubated with 60% DBS in 10% FBS-DMEM (Dulbecco's Modified Eagle's Media) and starvated with 0¾ FBS-D EM for 24 hours: warmed twice with PBS and irradiated with UV light. Each medium (1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid, amentoflavon, and sigma) was treated at a concentration of 2 ug / ml while changing the medium with 0% FBS-DMEM, followed by incubation for 48 hours. (Control handles DMS0). Collecting the medium and loading the same amount of medium to confirm the MMP-1 by Western blot, the protein was extracted from the cells to load the cell lysate in the same amount to confirm the expression of alpha-tubulin in Western blot.

As a result (Fig. 4), 1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid and amentoflavones It was confirmed that both amentoflavon) had an effect of suppressing the expression of MMP-1 (collagenase), and in particular, the effect of amentoflavon was excellent.

Example 4

<71> Evaluation of Skin Moisturizing Effect

<72> To examine the skin moisturizing effect of a substance that regulates the expression of the ABH antigen, a test substance was applied to 14 healthy males and females (7 males and 7 females) in their 20s to 30s. It was applied to the site.

<73> As the test substance, 0.2% of the substance that controls the expression of ABH antigen was diluted. Glycerine 5% was used as a positive control. The skin moisture content at the beginning, after 2 days, after 7 days, and after 11 days of the test substance was measured according to the following method with a coronometer (Corneometer CM825 (C + KGmbH, Germany)), and the results are shown in Table 1 below. .

<74> <Method of measuring Koniometer>

Principle: The amount of moisture present in the skin's epidermis is measured by electrical measurement, and the moisture level is measured by numerically calculating the amount of moisture.

<? 6> 1. Place the probe of the Koniometer on the area of skin to be measured.

2. When the probe is pressed on the skin, the electrical conductivity of the skin is quantified through the sensor and displayed on the screen.

3. The average value is obtained by repeating the measurement three times at each site.

<79> [Table 1]

As can be seen in Table 1 above, when the substance regulating the expression of the ABH antigen according to the present invention is applied to the skin, the skin moisture content tends to increase statistically (paired T-test, p <0.01 ) And skin moisture was maintained 11 days after application. Therefore, the composition containing a substance that regulates the expression of the ABH antigen according to the present invention was found to have excellent skin moisturizing power by effectively preserving the moisture of the skin after application.

Hereinafter, the formulation example of the composition according to the present invention will be described, but the pharmaceutical composition and the cosmetic composition can be used in various formulations, which is intended to explain in detail only and not intended to limit the present invention.

<82> [Formulation Example 1] lotion

<83> A lotion is prepared according to a conventional method using the composition shown in the table below.

<84> [Table 2]

<85> [Formulation Example 2] Nutrition Cream

A nutritious cream is prepared according to a conventional method with the composition shown in the table below.

<87> [Table 3]

Formulation Example 3 Massage Cream

Massage cream is prepared according to a conventional method with the composition described in the table below.

<90> [Table 4]

<91> [Formulation Example 4] Pack

The pack is prepared according to a conventional method with the composition shown in the table below.

<93> [Table 5]

<94> [Formulation Example 5] Gel

Gels are prepared according to conventional methods using the compositions shown in the table below. <96> [Table 6]

<97> [Formulation Example 6] Ointment

Ointments were prepared in a conventional manner with the compositions shown in the table below.

<99> [Table 7]

<ιοο> [Example 1] soft capsule

<ιοι> 1,3-diccafeoylquinic acid, 1,5-dicafeoylquinic acid

(1,5-dicafeoylquinic acid) and one or more compounds in the group consisting of amentoflavon 0.0025g, vitamin C 0.0025g, red ginseng extract 50 mg, palm oil 2 mg, palm frond 8 mg of sulfur oil, 4 mg of lead, and 6 mg of lecithin were mixed and layered by 400 mg per 1 capsule according to a conventional method to prepare a soft capsule.

Preparation Example 2 Tablet

1,3-diaffeoylquinic acid (l, 3-dicaffeoykiuinic acid), 1,5-dicafeoylquinic acid

In the group consisting of (1,5-dicafeoylquinic acid) and amentoflavones (0.0025 g), one or more compounds 0.0025 g, vitamin C 0.0025 g, glucose 100 mg, heungsam extract 50 mg, starch 96 mg and magnesium stearate 4 mg The mixture was added, 40 mg of 30% ethanol was added to form granules, dried at 60 ^° C., and compressed into tablets using a tablet press.

Preparation Example 3 Granules

<105> 1,3-dicaffeoyyl quinic acid (1,3-dicaffeoykiuimc acid), 1,5-dicafeoyl quinic acid

In a group consisting of (1,5-dicafeoylquinic acid) and amentoflavon, one or more compounds containing 150 mg, 150 mg of vitamin C, 100 mg of glucose, 50 mg of hepatic ginseng extract and 600 mg of starch are mixed and 30% ethanol 100 mg of the granules were formed, followed by drying at 60 ° C. to form granules, which were then laminated to the fabric. The final weight of the content was 1 g.

<Example 4> Preparation Example 4 Drinks

1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid

In the group consisting of (1,5-dicafeoylquinic acid) and amentoflavon, 0.0025 g of one or more compounds, 0.0025 g of vitamin C, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water Were mixed and filled in bottles. The final dose of the contents was 200 ml.

Having described the specific part of the present invention in detail, such a specific description is only a preferred embodiment for those skilled in the art, and thus the scope of the present invention is not limited thereto. The point will be obvious. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

<109>

Industrial Applicability

<πο> The composition according to the present invention contains a substance regulating the expression of the ABH antigen as an active ingredient, and has an excellent anti-aging and moisturizing effect. The composition of the present invention can also be usefully used to alleviate or improve wrinkles by inhibiting MMP-1 expression.

Claims

[Range of request]

[Claim 11

Anti-aging composition comprising a substance that controls the expression of the ABH antigen as an active ingredient.

[Claim 2]

The method of claim 1,

The active ingredient is a substance for increasing the expression of the ABH antigen, anti-aging composition. [Claim 3]

The method of claim 1,

Substances that regulate the expression of the ABH antigen are 1,

One or more compounds selected from the group consisting of 1—3-dicaf feoylquinic acid, 1,5-dicafeoylquinic acid, and amentoflavon Or a derivative thereof or a pharmaceutically acceptable salt thereof.

[Claim 4]

The method of claim 1,

The composition comprises an agent for controlling the expression of the ABH antigen in an amount of 0.001% to 20% by weight based on the total weight of the composition, anti-aging composition.

[Claim 5]

The method of claim 1,

The active ingredient inhibits the expression of MMP1 (matrix 111 ^ 31101) 1 ^" ^ 11336), anti-aging composition.

[Claim 6]

Moisturizing composition comprising a substance that controls the expression of the ABH antigen as an active ingredient.

[Claim 7]

The method of claim 6,

The active ingredient is a substance that increases the expression of the ABH antigen, moisturizing composition.

[Claim 8]

The method of claim 6,

Substances that regulate the expression of the ABH antigen are 1,3-dicaffeoylquinic acid, 1,5-dicafeoylquinic acid, and amentoflavones. A moisturizing composition, which is at least one compound selected from the group consisting of (amentoflavon), derivatives thereof or pharmaceutically acceptable salts thereof.

[Claim 9]

The method of claim 6,

The composition is a moisturizing composition comprising a substance that controls the expression of the ABH antigen in an amount of 0.001% to 20% by weight relative to the total weight of the composition.

[Claim 10]

The composition according to any one of claims 1 to 9, wherein the composition is a cosmetic composition.

[Claim 11]

The composition of claim 1, wherein the composition is a pharmaceutical composition.